Advertisement
Advertisement
ARGX
argenx SE - ADR
782.17
USDSponsored
-5.14
-0.65%
May 08, 16:00 UTC -4
Closed
After-Market
797.88
+15.71
+2.01%
ARGX Earnings Reports
Positive Surprise Ratio
ARGX beat 23 of 41 last estimates.
56%
Next Report
Date of Next Report
Jul 23, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.47B
/$6.16
Implied change from Q1 26 (Revenue/ EPS)
+11.88%
/+11.59%
Implied change from Q2 25 (Revenue/ EPS)
+51.89%
/+64.71%
argenx SE - ADR earnings per share and revenue
On May 07, 2026, ARGX reported earnings of 5.52 USD per share (EPS) for Q1 26, beating the estimate of 5.47 USD, resulting in a 0.86% surprise. Revenue reached 1.31 billion, compared to an expected 1.34 billion, with a -2.13% difference. The market reacted with a -2.51% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of 6.16 USD, with revenue projected to reach 1.47 billion USD, implying an increase of 11.59% EPS, and increase of 11.88% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Gilead Sciences Inc
Report Date
May 07, 2026 For Q1 26
Estimate
$1.95
Actual
$2.02
Surprise
+3.97%
Edgewise Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.46
Surprise
+7.33%
Zai Lab Limited - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.46
Surprise
-860.33%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.38
Actual
-$0.45
Surprise
-16.10%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
-$0.01
Surprise
-249.25%
Cytek Biosciences, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.09
Actual
-$0.12
Surprise
-23.84%
Zura Bio Limited Class A Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.17
Actual
-$0.22
Surprise
-23.94%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Whitehawk Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.09
Actual
-$0.32
Surprise
-242.61%
FAQ
What were argenx SE - ADR's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, argenx SE - ADR reported EPS of $5.52, beating estimates by 0.86%, and revenue of $1.31B, -2.13% below expectations.
How did the market react to argenx SE - ADR's Q1 2026 earnings?
The stock price moved down -2.51%, changed from $807.55 before the earnings release to $787.31 the day after.
When is argenx SE - ADR expected to report next?
The next earning report is scheduled for Jul 23, 2026.
What are the forecasts for argenx SE - ADR's next earnings report?
Based on --
analysts, argenx SE - ADR is expected to report EPS of $6.16 and revenue of $1.47B for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement